Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression - PubMed (original) (raw)
. 1996 May 15;56(10):2417-21.
Affiliations
- PMID: 8625321
Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression
R S Tan et al. Cancer Res. 1996.
Abstract
The transcriptional activator IFN regulatory factor 1 (IRF-1) and its antagonistic repressor IRF-2 are regulators of the IFN system. IRF-1 also manifests tumor suppressive activity, and its inactivation could contribute to the development of human hematopoietic malignancies. Here, we report the identification of the lysyl oxidase gene as a target gene of IRF-1. An IRF response element was identified in the lysyl oxidase gene promoter. We also demonstrate that the transformed phenotype of ras-expressing embryonic fibroblasts with a null mutation in the IRF-1 allele could be suppressed by the expression of the lysyl oxidase cDNA, implicating its potential role in tumor suppression. Thus, the regulation of the lysyl oxidase gene by IRF-1 could contribute to the multistep process of malignant transformation.
Similar articles
- IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
Kröger A, Dallügge A, Kirchhoff S, Hauser H. Kröger A, et al. Oncogene. 2003 Feb 20;22(7):1045-56. doi: 10.1038/sj.onc.1206260. Oncogene. 2003. PMID: 12592391 - Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Nguyen H, Mustafa A, Hiscott J, Lin R. Nguyen H, et al. Oncogene. 1995 Aug 3;11(3):537-44. Oncogene. 1995. PMID: 7630638 - Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis.
Kirchhoff S, Hauser H. Kirchhoff S, et al. Oncogene. 1999 Jun 24;18(25):3725-36. doi: 10.1038/sj.onc.1202704. Oncogene. 1999. PMID: 10391680 - [Functional role of IRF--family transcription factors].
Tanaka N. Tanaka N. Tanpakushitsu Kakusan Koso. 2000 Jun;45(9 Suppl):1551-9. Tanpakushitsu Kakusan Koso. 2000. PMID: 10879133 Review. Japanese. No abstract available. - Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1.
Taniguchi T, Tanaka N, Taki S. Taniguchi T, et al. Eur Cytokine Netw. 1998 Sep;9(3 Suppl):43-8. Eur Cytokine Netw. 1998. PMID: 9831185 Review.
Cited by
- miR-106b-5p Inhibits IRF1/IFN-β Signaling to Promote M2 Macrophage Polarization of Glioblastoma.
Shi Y, Zhang B, Zhu J, Huang W, Han B, Wang Q, Qi C, Wang M, Liu F. Shi Y, et al. Onco Targets Ther. 2020 Jul 30;13:7479-7492. doi: 10.2147/OTT.S238975. eCollection 2020. Onco Targets Ther. 2020. PMID: 32801770 Free PMC article. - Characterizing a human lysyl oxidase chromosomal domain.
Martins RP, Krawetz SA. Martins RP, et al. Mol Biotechnol. 2000 Jul;15(3):225-35. doi: 10.1385/MB:15:3:225. Mol Biotechnol. 2000. PMID: 10986698 Review. - Expression and DNA binding activity of the recombinant interferon regulatory factor-1 (IRF-1) of mouse.
Upreti M, Rath PC. Upreti M, et al. Mol Biol Rep. 2005 Jun;32(2):103-16. doi: 10.1007/s11033-004-6940-3. Mol Biol Rep. 2005. PMID: 16022283 - Cloning and characterization of a fourth human lysyl oxidase isoenzyme.
Mäki JM, Kivirikko KI. Mäki JM, et al. Biochem J. 2001 Apr 15;355(Pt 2):381-7. doi: 10.1042/0264-6021:3550381. Biochem J. 2001. PMID: 11284725 Free PMC article. - Lysyl oxidase: a potential target for cancer therapy.
Siddikuzzaman, Grace VM, Guruvayoorappan C. Siddikuzzaman, et al. Inflammopharmacology. 2011 Jun;19(3):117-29. doi: 10.1007/s10787-010-0073-1. Epub 2010 Nov 24. Inflammopharmacology. 2011. PMID: 21107914 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources